AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32066404 — intervention group
Group type: COMPARATOR
Intervention: Usual-practice wait-list control group.
Number of subjects: 0
Study 32066404 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldilocks work principle intervention.
Number of subjects: 0
Study 34454653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib
Number of subjects: 228
Study 34454653 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 228
Study 34034822 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based educational intervention
Number of subjects: 0
Study 34034822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36334250 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block (QLB)
Number of subjects: 75
Study 36334250 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 75
Study 36334250 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse abdominis plane block (TAPB)
Number of subjects: 75
Study 33649451 — intervention group
Group type: COMPARATOR
Intervention: Bladder antimuscarinics (oxybutynin, propiverine, tolterodine, solifenacin, trospium, darifenacin, and fesoterodine) used for at least 1 year before the index date.
Number of subjects: 2
Study 33649451 — intervention group
Group type: COMPARATOR
Intervention: No bladder antimuscarinic treatment (control group).
Number of subjects: 2
Study 33350739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (app) for self-exercise program
Number of subjects: 200
Study 33350739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (app) with real-time feedback
Number of subjects: 200
Study 33350739 — intervention group
Group type: COMPARATOR
Intervention: Physical education data (booklets)
Number of subjects: 200
Study 34112019 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard semi-permeable dressing and clear tape with cyanoacrylate glue (SPD + CG)
Number of subjects: 350
Study 34112019 — intervention group
Group type: COMPARATOR
Intervention: Standard semi-permeable dressing and clear tape (SPD)
Number of subjects: 350
Study 32909511 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ), 20 mg thrice daily orally 24 hours before and 72 hours after PCI
Number of subjects: 310
Study 32909511 — intervention group
Group type: COMPARATOR
Intervention: Control group (hydration only)
Number of subjects: 310
Study 32909511 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 310
Study 32960532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 154
Study 32960532 — intervention group
Group type: COMPARATOR
Intervention: Low-dose bupivacaine
Number of subjects: 154
Study 36129693 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 9673
Study 36129693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9673
Study 32602273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 84
Study 32602273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 35860451 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 201
Study 35860451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 34321057 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic befriending intervention
Number of subjects: 1440
Study 34321057 — intervention group
Group type: COMPARATOR
Intervention: General enquiry phone call (control)
Number of subjects: 1440
Study 32418538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon character condition (n = 1789)
Number of subjects: 3755
Study 32418538 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 1966)
Number of subjects: 3755
Study 35221673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (5 mg) alone
Number of subjects: 24
Study 35221673 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg) alone
Number of subjects: 24
Study 35221673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil plus amlodipine
Number of subjects: 24
Study 35221673 — intervention group
Group type: COMPARATOR
Intervention: Combined administration of tadalafil and amlodipine
Number of subjects: 24
Study 32591869 — intervention group
Group type: COMPARATOR
Intervention: Demineralized bovine bone mineral (DBBM) and a gingival soft tissue punch
Number of subjects: 21
Study 32591869 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bovine bone mineral (DBBM) and a hemostatic gelatin sponge
Number of subjects: 21
Study 32128907 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rapamycin solution (1 mg/mL) applied twice daily for 3 months
Number of subjects: 76
Study 32128907 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate ointment 0.05% in Orabase® applied twice daily for 3 months
Number of subjects: 76
Study 34716281 — intervention group
Group type: EXPERIMENTAL
Intervention: Timapiprant
Number of subjects: 38
Study 34716281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32209911 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous resection
Number of subjects: 105
Study 32209911 — intervention group
Group type: COMPARATOR
Intervention: Delayed resection
Number of subjects: 105
Study 34855053 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referential future thinking induction
Number of subjects: 63
Study 34855053 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referential past thinking induction
Number of subjects: 63
Study 34855053 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 63
Study 32460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification by centre for clustering management
Number of subjects: 50
Study 32460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Defining a minimum expertise level for treatment provider
Number of subjects: 50
Study 32460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience in expertise-based designs
Number of subjects: 50
Study 32460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for clustering during analysis
Number of subjects: 50
Study 32460815 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of learning
Number of subjects: 50
Study 36088327 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 ≥ 32.0 ng/mL
Number of subjects: 568
Study 36088327 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 16.5–32.0 ng/mL
Number of subjects: 568
Study 36088327 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP ≥ 337 ng/L
Number of subjects: 568
Study 36088327 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP 89–337 ng/L
Number of subjects: 568
Study 36088327 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI ≥ 7.8 ng/L
Number of subjects: 568
Study 36088327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac score based on sST2, hs-cTnI, and NT-proBNP
Number of subjects: 568
Study 36088327 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2, hs-cTnI, and NT-proBNP
Number of subjects: 568
Study 34675189 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate (MPH)
Number of subjects: 50
Study 34675189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 34619447 — intervention group
Group type: EXPERIMENTAL
Intervention: URH+CM (Contingency Management)
Number of subjects: 98
Study 34619447 — intervention group
Group type: COMPARATOR
Intervention: URH (Control)
Number of subjects: 98
Study 34245689 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG
Number of subjects: 36000
Study 34245689 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA
Number of subjects: 36000
Study 34245689 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM
Number of subjects: 36000
Study 35962359 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations with primary care nurses about child's weight (responsive, non-blaming approach).
Number of subjects: 17
Study 35962359 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations with primary care nurses about child's weight (presentation of the topic).
Number of subjects: 17
Study 35962359 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations with primary care nurses about child's weight.
Number of subjects: 17
Study 34358372 — intervention group
Group type: EXPERIMENTAL
Intervention: DenseNet121 model
Number of subjects: 700
Study 34358372 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster R‐CNN model
Number of subjects: 700
Study 35143411 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/L buffered MS‐222 for 15 minutes
Number of subjects: 24
Study 35143411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/L buffered MS‐222 for 15 minutes
Number of subjects: 24
Study 35143411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/L buffered MS‐222 for 15 minutes, then placed in freshwater for 3 hours
Number of subjects: 24
Study 35143411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/L buffered MS‐222 for 15 minutes, then placed in freshwater for 18 hours
Number of subjects: 24
Study 35143411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/L buffered MS‐222 for 60 minutes, then placed in freshwater for 3 hours
Number of subjects: 24
Study 34534897 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich diet (PR-diet)
Number of subjects: 51
Study 34534897 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 51
Study 35285282 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (ten 1-hour sessions, twice weekly)
Number of subjects: 80
Study 35285282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 32028900 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (22 smokers)
Number of subjects: 49
Study 32028900 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (27 non-smokers)
Number of subjects: 49
Study 35443843 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming
Number of subjects: 36
Study 35443843 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercises
Number of subjects: 36
Study 33956256 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose/sodium hyaluronate eye drops b.i.d (Group A)
Number of subjects: 135
Study 33956256 — intervention group
Group type: COMPARATOR
Intervention: 0.9% unpreserved sodium chloride eye drops b.i.d (Group B)
Number of subjects: 135
Study 32421353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural fibrinolytic therapy (IPFT)
Number of subjects: 32
Study 32421353 — intervention group
Group type: COMPARATOR
Intervention: Early medical thoracoscopy (MT)
Number of subjects: 32
Study 36084154 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 180
Study 36084154 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 180
Study 32014032 — intervention group
Group type: EXPERIMENTAL
Intervention: S44819 150 mg bid
Number of subjects: 580
Study 32014032 — intervention group
Group type: EXPERIMENTAL
Intervention: S44819 300 mg bid
Number of subjects: 580
Study 32014032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study 36054369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate intranasal spray
Number of subjects: 80
Study 36054369 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride intranasal spray (placebo)
Number of subjects: 80
Study 34099390 — intervention group
Group type: EXPERIMENTAL
Intervention: Just Do You engagement program
Number of subjects: 0
Study 34099390 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 34510966 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling sessions (3 sessions)
Number of subjects: 70
Study 33508918 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT (XELOX chemotherapy: capecitabine + oxaliplatin) with concurrent radiotherapy (45 Gy, 25 times, 1.8 Gy/d, 5 times/week)
Number of subjects: 150
Study 33508918 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT (XELOX chemotherapy: capecitabine + oxaliplatin)
Number of subjects: 150
Study 32819528 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force–guided radiofrequency ablation
Number of subjects: 346
Study 32819528 — intervention group
Group type: COMPARATOR
Intervention: Cryoballoon ablation
Number of subjects: 346
Study 35820547 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg daily
Number of subjects: 666
Study 35820547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666
Study 35820547 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 666
Study 34639109 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal injection of recombinant human follicle-stimulating hormone (rhFSH)
Number of subjects: 0
Study 34639109 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal injection of recombinant human follicle-stimulating hormone (rhFSH)
Number of subjects: 0
Study 34639109 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily abdominal or vaginal injections of rhFSH (1 IU twice daily for 4 days)
Number of subjects: 0
Study 34639109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent vaginal injections of rhFSH (4 IU every other day for two doses)
Number of subjects: 0
Study 34639109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent abdominal or vaginal injections of rhFSH
Number of subjects: 0
Study 34639109 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34358713 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation (iTBS) over bilateral posterior superior temporal sulcus (pSTS) for 5 consecutive days
Number of subjects: 13
Study 34358713 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation (iTBS)
Number of subjects: 13
Study 34358713 — intervention group
Group type: COMPARATOR
Intervention: sham control (inion)
Number of subjects: 13
Study 34285426 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg intravitreal bevacizumab
Number of subjects: 51
Study 34285426 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravitreal triamcinolone
Number of subjects: 51
Study 34285426 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab and 1 mg intravitreal triamcinolone (combined treatment)
Number of subjects: 51
Study 34285426 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study 616886751 — intervention group
Group type: EXPERIMENTAL
Intervention: PDCA intervention
Number of subjects: 92
Study 34855039 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care approach
Number of subjects: 15
Study 34855039 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 15
Study 32901432 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil/armodafinil
Number of subjects: 0
Study 32901432 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional psychostimulants
Number of subjects: 0
Study 32901432 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 0
Study 32901432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 0
Study 32901432 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0
Study 32901432 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 32901432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 0
Study 32901432 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 0
Study 32901432 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0
Study 32901432 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 32454078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating situation at friend's place
Number of subjects: 1046
Study 32454078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating situation at home
Number of subjects: 1046
Study 32454078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating situation at a restaurant abroad
Number of subjects: 1046
Study 32454078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating situation at a domestic restaurant
Number of subjects: 1046
Study 34029235 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercises with extracorporeal shockwave therapy (SWT group)
Number of subjects: 119
Study 34029235 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercises with sham shockwave therapy (control group)
Number of subjects: 119
Study 32856146 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term stenting (Group B)
Number of subjects: 62
Study 32856146 — intervention group
Group type: COMPARATOR
Intervention: Long-term stenting (Group A)
Number of subjects: 62
Study 32856146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 62
Study 35060868 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation training (Breathe, Talk, See, Focus mental performance tool)
Number of subjects: 61
Study 34301749 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 215
Study 34301749 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (PC)
Number of subjects: 215
Study 32186523 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone spray 0.25% for 2 weeks with twice-daily telephone call reminders
Number of subjects: 12
Study 32186523 — intervention group
Group type: COMPARATOR
Intervention: Desoximetasone spray 0.25% for 2 weeks without reminders
Number of subjects: 12
Study 35813434 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal ultrasound monitoring using ONLM algorithm with optimal pulmonary compliance titration of PEEP.
Number of subjects: 120
Study 35813434 — intervention group
Group type: COMPARATOR
Intervention: Fixed PEEP=5 cmH2O in control group.
Number of subjects: 120
Study 35813434 — intervention group
Group type: EXPERIMENTAL
Intervention: ONLM algorithm compared to NLM and Bayes Shrink denoising algorithm.
Number of subjects: 120
Study 33070176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide AUC/MIC below 8.42
Number of subjects: 220
Study 33070176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide AUC/MIC below 2.79
Number of subjects: 220
Study 33070176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin AUC/MIC below 435.45
Number of subjects: 220
Study 33070176 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid AUC >21.78 mg · h/L
Number of subjects: 220
Study 33070176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin AUC >82.01 mg · h/L
Number of subjects: 220
Study 35785423 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard splint therapy
Number of subjects: 91
Study 35785423 — intervention group
Group type: COMPARATOR
Intervention: Soft splint therapy
Number of subjects: 91
Study 33434035 — intervention group
Group type: EXPERIMENTAL
Intervention: Conidia suspension with a concentration of 5×10^5/ml sprayed on fruits; maintained high humidity for 3 days
Number of subjects: 6
Study 33434035 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 6
Study 32795283 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target physiotherapy strategy
Number of subjects: 624
Study 32795283 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative care
Number of subjects: 624
Study 33978983 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 153
Study 33252568 — intervention group
Group type: EXPERIMENTAL
Intervention: OA-CXL (accelerated CXL with systemic oxygen at 5 L/min for 10 minutes)
Number of subjects: 47
Study 33252568 — intervention group
Group type: EXPERIMENTAL
Intervention: OA-CXL
Number of subjects: 47
Study 33252568 — intervention group
Group type: COMPARATOR
Intervention: A-CXL (accelerated CXL without supplemental oxygen)
Number of subjects: 47
Study 33252568 — intervention group
Group type: COMPARATOR
Intervention: C-CXL (conventional CXL according to the Dresden protocol)
Number of subjects: 47
Study 35014128 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided therapy with spironolactone
Number of subjects: 349
Study 35014128 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 349
Study 33309030 — intervention group
Group type: EXPERIMENTAL
Intervention: MR holographic guidance (MRHG)
Number of subjects: 34
Study 33309030 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine 3D reconstruction)
Number of subjects: 34
Study 33309030 — intervention group
Group type: EXPERIMENTAL
Intervention: MRHG
Number of subjects: 34
Study 33309030 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 35147387 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Nephrectomy (PN)
Number of subjects: 13177
Study 35147387 — intervention group
Group type: COMPARATOR
Intervention: Radical Nephrectomy (RN)
Number of subjects: 13177
Study 33626248 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated machine perfusion
Number of subjects: 160
Study 33626248 — intervention group
Group type: COMPARATOR
Intervention: Conventional static cold storage
Number of subjects: 160
Study 36495882 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2
Number of subjects: 330
Study 36495882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 34375393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle therapy plus testosterone (LT+Test)
Number of subjects: 83
Study 34375393 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle therapy plus placebo (LT+Pbo)
Number of subjects: 83
Study 32436455 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus ASA 100 mg
Number of subjects: 0
Study 32436455 — intervention group
Group type: COMPARATOR
Intervention: ASA 100 mg
Number of subjects: 0
Study 35060222 — intervention group
Group type: EXPERIMENTAL
Intervention: Untire app intervention
Number of subjects: 799
Study 35060222 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 799